U.K.’s NICE Clears Lucentis For Treating Diabetic Macular Edema
This article was originally published in The Pink Sheet Daily
The U.K.’s cost-effectiveness agency gave a clear OK to Lucentis as an option for treating visual impairment caused by diabetic macular edema after Novartis provided a bigger price discount and updated analyses showing the drug’s superior relative effect among a sub-group of people with the condition.
You may also be interested in...
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.